JINS HOLDINGS Inc. (TYO:3046)

Inozyme Pharma Ratios and Metrics

Market cap in millions JPY. Fiscal year is September - August.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 7, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020
Market Capitalization	188,834	121,368	80,290	99,546	167,583	170,851
Market Cap Growth	130.59%	51.16%	-19.34%	-40.60%	-1.91%	21.39%
Enterprise Value	184,310	119,434	83,270	100,009	167,621	172,701
Last Close Price	8090.00	5162.15	3370.98	4133.94	6941.16	7033.25
PE Ratio	24.54	25.98	45.57	132.73	50.91	101.28
Forward PE	22.05	28.42	22.80	35.78	37.87	44.44
PS Ratio	2.02	1.46	1.10	1.49	2.62	2.84
PB Ratio	6.41	4.74	3.69	4.88	8.29	9.62
P/TBV Ratio	7.43	5.26	4.06	5.47	9.32	11.01
P/FCF Ratio	-	13.33	25.59	57.54	48.30	31.17
P/OCF Ratio	-	11.05	13.26	22.67	33.13	22.05
PEG Ratio	0.89	0.66	0.25	2.31	1.20	1.20
EV/Sales Ratio	1.97	1.44	1.14	1.50	2.62	2.87
EV/EBITDA Ratio	12.62	11.10	10.72	15.96	21.64	20.50
EV/EBIT Ratio	15.79	15.24	17.18	30.16	33.19	30.88
EV/FCF Ratio	-	13.12	26.54	57.81	48.31	31.50
Debt / Equity Ratio	0.18	0.48	0.57	1.12	1.16	1.38
Debt / EBITDA Ratio	-	1.15	1.61	3.64	3.01	2.91
Debt / FCF Ratio	-	1.36	3.99	13.19	6.73	4.47
Asset Turnover	-	1.68	1.47	1.24	1.20	1.34
Inventory Turnover	-	3.83	3.26	2.75	2.85	2.70
Quick Ratio	0.85	0.98	1.53	1.14	2.57	2.27
Current Ratio	1.33	1.26	2.11	1.46	3.16	2.73
Return on Equity (ROE)	-	19.72%	8.35%	3.69%	17.33%	8.41%
Return on Assets (ROA)	-	9.90%	6.08%	3.85%	5.93%	7.77%
Return on Capital (ROIC)	-	13.56%	7.82%	4.78%	7.35%	10.07%
Return on Capital Employed (ROCE)	35.10%	27.60%	14.40%	10.40%	11.90%	13.80%
Earnings Yield	4.12%	3.85%	2.20%	0.75%	1.96%	0.99%
FCF Yield	-	7.50%	3.91%	1.74%	2.07%	3.21%
Dividend Yield	1.16%	1.18%	1.13%	0.41%	0.65%	0.36%
Payout Ratio	-	22.59%	17.20%	115.07%	35.42%	70.95%
Buyback Yield / Dilution	4.44%	2.10%	2.14%	-0.24%	-3.22%	-2.77%
Total Shareholder Return	5.60%	3.28%	3.27%	0.17%	-2.58%	-2.42%

Updated Jan 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.